Adrenergic beta-1 Receptor Antagonists
"Adrenergic beta-1 Receptor Antagonists" is a descriptor in the National Library of Medicine's controlled vocabulary thesaurus,
MeSH (Medical Subject Headings). Descriptors are arranged in a hierarchical structure,
which enables searching at various levels of specificity.
Drugs that bind to and block the activation of ADRENERGIC BETA-1 RECEPTORS.
| Descriptor ID |
D058671
|
| MeSH Number(s) |
D27.505.519.625.050.200.200.100 D27.505.696.577.050.200.200.100
|
| Concept/Terms |
Adrenergic beta-1 Receptor Antagonists- Adrenergic beta-1 Receptor Antagonists
- Adrenergic beta 1 Receptor Antagonists
- Adrenergic beta1-Antagonists
- Adrenergic beta1 Antagonists
- beta1-Antagonists, Adrenergic
- beta-1 Adrenergic Blocking Agents
- beta 1 Adrenergic Blocking Agents
- Adrenergic beta-1 Antagonists
- Adrenergic beta 1 Antagonists
- Antagonists, Adrenergic beta-1
- beta-1 Antagonists, Adrenergic
- Adrenergic beta-1 Receptor Blockers
- Adrenergic beta 1 Receptor Blockers
|
Below are MeSH descriptors whose meaning is more general than "Adrenergic beta-1 Receptor Antagonists".
Below are MeSH descriptors whose meaning is more specific than "Adrenergic beta-1 Receptor Antagonists".
This graph shows the total number of publications written about "Adrenergic beta-1 Receptor Antagonists" by people in this website by year, and whether "Adrenergic beta-1 Receptor Antagonists" was a major or minor topic of these publications.
To see the data from this visualization as text,
click here.
| Year | Major Topic | Minor Topic | Total |
|---|
| 2014 | 1 | 0 | 1 |
| 2018 | 1 | 0 | 1 |
| 2019 | 1 | 0 | 1 |
| 2020 | 1 | 0 | 1 |
| 2021 | 1 | 0 | 1 |
To return to the timeline,
click here.
Below are the most recent publications written about "Adrenergic beta-1 Receptor Antagonists" by people in Profiles.
-
Propranolol inhibits cavernous vascular malformations by ß1 adrenergic receptor antagonism in animal models. J Clin Invest. 2021 02 01; 131(3).
-
Examination of Metoprolol Pharmacokinetics and Pharmacodynamics Across CYP2D6 Genotype-Derived Activity Scores. CPT Pharmacometrics Syst Pharmacol. 2020 12; 9(12):678-685.
-
Genome-Wide Meta-Analysis of Blood Pressure Response to ß1-Blockers: Results From ICAPS (International Consortium of Antihypertensive Pharmacogenomics Studies). J Am Heart Assoc. 2019 08 20; 8(16):e013115.
-
Genome-Wide Association Approach Identified Novel Genetic Predictors of Heart Rate Response to ß-Blockers. J Am Heart Assoc. 2018 02 24; 7(5).
-
Surgical Intervention for Medically Refractory Hyperthyroidism. Pediatr Ann. 2016 May 01; 45(5):e171-5.
-
Spironolactone for resistant hypertension--hard to resist? Lancet. 2015 Nov 21; 386(10008):2032-2034.
-
Therapy: atenolol versus metoprolol tartrate--conflicting outcomes data. Nat Rev Nephrol. 2014 Nov; 10(11):617-8.
-
Predictors for glucose change in hypertensive participants following short-term treatment with atenolol or hydrochlorothiazide. Pharmacotherapy. 2014 Nov; 34(11):1132-40.
-
YKL-40 in pediatric asthma, MUC5B promoter polymorphism in idiopathic pulmonary fibrosis, and esmolol in septic shock. Am J Respir Crit Care Med. 2014 May 01; 189(9):1138-40.
-
Effects of nebivolol on aortic compliance in patients with diabetes and maximal renin angiotensin system blockade: the EFFORT study. J Clin Hypertens (Greenwich). 2013 Jul; 15(7):473-9.